Fact CheckerSign in

NCT06916104Enrolling by invitation

Impact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmatic Patients Followed at Poitiers University Hospital on Biotherapy

Source: ClinicalTrials.gov · Last updated 8 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The aim of this study is to take stock of the situation of adult patients with severe asthma on biotherapy, followed up at Poitiers University Hospital, and in particular to increase our knowledge of factors predictive of response to biotherapy. The main aim is to improve the management of adult severe asthma patients treated with biotherapy, according to their allergic status.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
100 (estimated)
First submitted
31 Mar 2025
Start date
1 Mar 2024
Primary completion date
31 Mar 2025
Lead sponsor
Poitiers University Hospital
Diseases
Asthma
NCT number
NCT06916104

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Mar 2024 to the primary completion date, 31 Mar 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Absence of allergological assessment
  • Patient's refusal to participate in study

Who the study is looking for

  • Severe asthma patient on biotherapy
  • Age \> or = 18 years
  • Follow-up at Poitiers University Hospital

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.